Sign in
Taking people in South AfricaPhase 2

Tests nebulised RESP30TB with standard drugs for lung tuberculosis

Tests a nebulised drug added to standard treatment in adults with new lung tuberculosis.

Key facts

Who runs it
Thirty Respiratory Limited
Where
Cape Town, South AfricaSee the site
Trial code
Registry title
Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis
Status
Recruiting
Phase
Phase 2
People taking part
24 people, planned
Started
13 Oct 2025
Planned end
15 Nov 2026
Type of study
Interventional, 2 groups
Treatments tested
  • RESP30TB
  • HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)
Record updated
12 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 65 with newly diagnosed lung tuberculosis that can be treated with rifampicin. It tests an inhaled (nebulised) drug called RESP30TB.

Age
18 to 65 years
Sex
All sexes can join.
Disease stage
Newly diagnosed pulmonary (lung) tuberculosis that is rifampicin susceptible, confirmed by molecular testing.
Earlier treatment
People cannot have had any drug active against M.tb for this episode of TB.
Biomarker or test result
Rifampicin susceptibility on molecular testing. Methaemoglobin saturation (SpMet) must not be above 3%. Lung function test FEV1 of 40% or more.

Main reasons for not taking part

  • HIV positive with CD4 below 350 cells/mm3, or taking antiviral therapy (ART)
  • Pregnant or breast-feeding women
  • Taking part in another study with investigational agents within 8 weeks before screening
  • Taking immunosuppressive medicines such as TNF-alpha inhibitors within 2 weeks before screening
  • Taking NO or NO donor agents, phosphodiesterase inhibitors or lung surfactant drugs within 30 days before screening

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Provide written, informed consent prior to all trial-related procedures and agree to undergo all trial procedures
  • Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive
  • Newly diagnosed pulmonary TB
  • Rifampicin susceptible pulmonary TB as determined by molecular testing
  • Ability to produce an adequate volume of sputum as estimated from a pre-treatment overnight sputum collection sample (estimated 10 mL or more)
  • Spirometry performed during screening with a Forced Expiration Volume in the first second (FEV1) of ≥ 40%
  • Be of non-childbearing potential or willing to use effective methods of contraception, as defined in section 4.3.4

Who cannot take part

  • HIV positive AND CD4 < 350 cells/mm3 OR are receiving antiviral therapy (ART)
  • Participation in other clinical studies with investigational agents within 8 weeks prior to screening
  • Treatment received for this episode of TB with any drug active against M.tb
  • Treatment with immunosuppressive medications such as TNF-alpha inhibitors within 2 weeks prior to screening, or systemic corticosteroids for more than 7 days within 2 weeks prior to screening
  • Treatment with NO and other NO donor agents, phosphodiesterase inhibitors and lung surfactant drugs, within 30 days prior to screening
  • Baseline Methaemoglobin saturation (SpMet) >3%
  • Female patients who is pregnant or breast-feeding
  • Patients planning to conceive a child within the anticipated period of trial participation and for at least 90 days after the last dose of IMP in the trial

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial is currently available in South Africa.

  • TASK Clinical Research CentreCape Town, South AfricaContact: Lukhanyile KeteloTaking people

About the trial

What the trial wants to find out

A Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of Nebulised RESP30TB in Adults with Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis

The 2 groups in the trial

  • RESP30TBTreatment being tested

    Stage 1 - Inhaled RESP30TB 6ml via nebulisation three times daily

  • RESP30TB + HRZETreatment being tested

    Stage 2 - Inhaled RESP30TB 6 ml dosed via nebulisation administered three times daily in combination with HRZE taken orally once daily

    Treatment: RESP30TB and HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of Nebulised RESP30TB in Adults With Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis
Plain-language title
Tests nebulised RESP30TB with standard drugs for lung tuberculosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT07073638, who can take part
Record updated
12 January 2026